Peptides Beyond GLP-1: Silicon Valley's Unregulated Injectable Compound Trend
Synthetic injectable peptides beyond GLP-1 (Ozempic) are surging in popularity, especially in tech circles. People order unregulated compounds like BPC-157, PT-141, and GHK-Cu from Chinese factories via Discord for $15/vial (resold for $200+) for muscle repair, skin/hair, focus, and fat loss. No clinical trials exist for most. The market could reach $1 trillion. FDA-approved GLP-1 drugs are proven; everything else is experimental with unknown long-term risks.
Synthetic injectable peptides — chains of amino acids that trigger specific body functions — are experiencing explosive popularity beyond the well-studied GLP-1 class (Ozempic, Wegovy). The trend is driven by unregulated compounds manufactured in Chinese factories and distributed via Discord servers and gray-market suppliers. ## The Landscape | Peptide | Claimed Benefit | Evidence Level | |---------|----------------|----------------| | GLP-1 (Ozempic, Wegovy, Retatrutide) | Weight loss | FDA-approved, extensively studied, proven | | BPC-157 (Body Protection Compound) | Muscle/tendon/gut repair | Animal studies only; no human clinical trials | | PT-141 (Bremelanotide) | Sexual function enhancement | FDA-approved as Vyleesi for female HSDD only | | GHK-Cu | Skin/hair regeneration, wound healing | Topical studies exist; injectable use unstudied | | Thymosin Alpha-1 | Immune system modulation | Approved in some countries for hepatitis; off-label use common | | Epithalon | Anti-aging via telomerase activation | Extremely limited human data | ## Supply Chain Compounds are synthesized in unregulated Chinese factories, sold wholesale for ~$15/vial, and resold through gray-market channels for $200+. Quality control is inconsistent — purity, dosage accuracy, and contamination risk are unknowns. Some users import powder and reconstitute themselves. ## The Risk Assessment FDA-approved GLP-1 drugs have robust safety data from large-scale clinical trials. Everything else in the peptide trend operates without meaningful human safety data. BPC-157 — the most popular non-GLP-1 peptide — has zero published human clinical trials. Long-term effects of chronic injection of research-grade compounds are entirely unknown. Some physicians are prescribing these through compounding pharmacies; others consider the trend dangerous. ## Market Scale Analyst estimates project the broader peptide therapeutics market could reach $1 trillion. The unregulated gray market is a fraction of this but growing rapidly, particularly in San Francisco tech circles where self-experimentation culture is strong.